RecruitingNCT05434325

TESTING -ON Post-Trial ObservatioNal Cohort Study

Studying IgA Nephropathy

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: The George Institute
Principal Investigator: Hong Zhang, Prof
Peking University Institute of Nephrology
Enrollment: 366 enrolled
Eligibility: 18-100 years · All sexes
Timeline: 2022 – 2027

Study locations (30)

Nepean Hospital, Kingswood, New South Wales, Australia
Royal North Shore Hospital, St Leonards, New South Wales, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
University of Calgary/Alberta Health Services, Calgary, Alberta, Canada
University of Alberta Hospitals, Edmonton, Alberta, Canada
St Pauls Hospital, Vancouver, British Columbia, Canada
St. Joseph's Healthcare, Hamiliton, Ontario, Canada
London Health Sciences Centre, London, Ontario, Canada
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Toronto General Hospital,, Toronto, Ontario, Canada
Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
Chinese PLA General Hospital (301 Hospital), Beijing, Beijing Municipality, China
The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital, Guangzhou, Guangzhou, Guangdong, China
Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
+15 more locations on ClinicalTrials.gov

Collaborators

Peking University Institute of Nephrology

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05434325 on ClinicalTrials.gov

Other trials for IgA Nephropathy

Additional recruiting or active studies for the same condition.

See all trials for IgA Nephropathy →

← Back to all trials